Modality
Vaccine
MOA
PI3Ki
Target
KRASG12D
Pathway
RAS/MAPK
PVMesoRCC
Development Pipeline
Preclinical
~Apr 2022
→ ~Jul 2023
Phase 1
Oct 2023
→ Feb 2025
Phase 1Current
NCT04931776
995 pts·PV
2023-10→2025-02·Completed
995 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-02-071.1y agoInterim· PV
2025-08-018mo agoFast Track· Meso
Trial Timeline
Q42024Q2Q3Q42025Q2Q3
P1
Complet…
Catalysts
Interim
2025-02-07 · 1.1y ago
PV
Fast Track
2025-08-01 · 8mo ago
Meso
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04931776 | Phase 1 | PV | Completed | 995 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D |